Is Red Cat Stock a Buy, Sell, or Hold for July 2025?
Relatively cheap and easy to build, drones allow targets to be hit with precision and are easy to operate. Consequently, the global defense drone market is projected to reach $88.1 billion by 2030, and Defense Secretary Pete Hegseth wants the United States to be the leader in drone warfare. Committing to 'unleashing American drone dominance' and promising to get rid of "restrictive policies' to boost drone manufacturing, Hegseth's comments spell optimism for drone stocks.
Palantir Just Launched Warp Speed for Warships. Does That Make PLTR Stock a Buy?
This Analyst Just Doubled His Price Target on AMD Stock
How High Can Nvidia Stock Go as Jensen Huang Heads to China?
Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines.
To that end, one of the companies that stands to benefit might be Red Cat (RCAT).
Red Cat has quite the corporate history. Initially founded in the mid-1980s as Oravest International, the company adopted its current name after Propware, a provider of open-source software and service platforms for the drone industry, acquired it through a share purchase agreement in 2019.
Currently valued at a market cap of $950 million, RCAT stock is down 20% on a YTD basis.
So, what can make Red Cat be a winner in the burgeoning drone industry? Let's have a closer look.
Red Cat has gradually built an impressive fleet of drones, ranging from nimble short-range quadcopters to longer-range fixed-wing hybrids with the additional benefit of offering flexible systems tailored to evolving defense needs.
One key product, the Teal 2, is notable for its stealth and utility. Despite its compact build, it packs powerful imaging tools, including high-grade thermal vision and optional electro-optical sensors. These allow the drone to perform in total darkness with remarkable clarity. Another product, the Black Widow, is engineered with contested airspace in mind. Designed to operate in electronically jammed environments, it serves as a tactical reconnaissance solution and was developed by Teal Drones, Red Cat's key subsidiary. Beyond these, Red Cat's portfolio includes the Golden Eagle and Edge 130, both of which are approved for use under the Department of Defense's Blue UAS framework, with a fourth model currently under review. If this receives approval, Red Cat would have a uniquely full-spectrum Blue UAS-compliant fleet.
On the other hand, financially, the company may be on the cusp of a breakout year. From first-quarter revenue of just $1.7 million, Red Cat has projected full-year sales could approach $120 million, largely driven by defense contracts. Specifically, the Black Widow has made it into the final evaluation stages of the U.S. Army's Short Range Reconnaissance (SRR) program, which could result in large-scale orders.
Beyond aerial systems, Red Cat is expanding into maritime autonomy. In May, the company formally entered the uncrewed surface vessel space, creating a second growth pillar. These surface vehicles can also serve as platforms for launching aerial drones.
Meanwhile, Red Cat is investing in software and production infrastructure. The company is integrating Athena AI for onboard target recognition, bringing real-time battlefield intelligence to its drones. In parallel, it has partnered with Palantir (PLTR) to deploy the Warp Speed manufacturing platform, which is intended to streamline operations, trim costs, and prepare for higher-volume fulfillment, particularly in anticipation of orders related to the SRR program or other federal opportunities.
Red Cat's present financial situation does not inspire confidence in the company. It is yet to be profitable, while its revenues in the most recent quarter declined along with a widening of losses.
Revenues for the quarter were at $1.7 million, down 75.4% from the previous year. Losses per share came in at $0.27, three times more from the previous year's loss of $0.09 per share.
Net cash outflow from operating activities widened to $15.9 million in Q1 2025 from $4.4 million in Q1 2024 as the company closed the quarter with a cash balance of $7.7 million. However, this was higher than the company's short-term debt of $2.7 million. What also further fortified the company's balance sheet was the $30 million fundraise with CEO Jeff Thompson asserting that the '$30 million capital raise positions us strongly to meet growing domestic and international demand in the second half of 2025.'
This, along with a stable cash position and an optimistic revenue outlook, reflects that the company's financials are on the path of improvement.
Red Cat has limited coverage on Wall Street, with just a single rating of 'Strong Buy' and a price target of $13 as tracked by Barchart. This denotes upside potential of about 27% from current levels.
On the date of publication, Pathikrit Bose did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
23 minutes ago
- Business Insider
Standard Chartered: Weak dollar to unlock opportunities in emerging markets and global equities
10 July 2025, Nairobi, Kenya: Standard Chartered announced today its Global Market Outlook for the second half of 2025, projecting a constructive but volatile environment for investors worldwide. The Bank sees significant implications for emerging markets investors including Africa, driven by expectations of a softer US dollar, resilient global equity markets and improving prospects for emerging-market assets. The report highlights that Global macro conditions remain mixed. In the United States, growth continues to be supported by resilient consumption and fiscal stimulus, though trade and policy uncertainty may temper momentum in the second half of the year. In Europe, fiscal easing increasingly offers support, but structural challenges persist while China's outlook is stabilising on the back of targeted stimulus and improving retail activity. Meanwhile, growth in India and ASEAN is expected to remain well-supported. Against this backdrop, the report outlines an investment strategy reflecting evolving risks and opportunities. We expect the US dollar to weaken over the next 6 to 12 months and have accordingly upgraded Asia (ex-Japan) equities and Emerging Market (EM) local-currency bonds to Overweight. Global equities also remain an Overweight position across portfolios, supported by healthy earnings, easing trade tensions, and controlled inflation (so far). Based on the report, 'Aas global markets transition into a new phase, emerging markets investors are well-positioned to capitalise on emerging opportunities. A weaker dollar historically supports returns across risk assets, particularly in emerging markets, which have long been core components of regional portfolios. Manpreet Gill, Chief Investment Officer of Africa, Middle East and Europe, Standard Chartered said: ' This outlook underscores a critical moment for investors in the region. As the global environment adjusts to weak dollar dynamics, shifting trade policies, and diverging central bank actions, investors in the emerging markets have an opportunity to reposition portfolios with greater international diversification. Asset classes such as emerging market bonds and equities across major regions (including non-US equities) are well-placed to help investors navigate volatility, capture income, and enhance portfolio resilience in today's shifting landscape.' In line with these themes, the report maintains a preference for USD-denominated bonds in the 5–7-year maturity range, citing them as the most attractive in terms of risk-adjusted returns, particularly as yields begin to ease from current levels. Meanwhile, Developed Market Investment Grade corporate bonds have been downgraded to Underweight due to tight yield premiums and slower inflows. Alternative investments are also in focus, with the Bank highlighting gold as a core allocation, supported by strong central bank demand and its role as a diversifier when bonds offer less downside protection.
Yahoo
2 hours ago
- Yahoo
These 2 Momentum Stocks Got a Bullish Nod — Here's Why They Could Reach New Highs
Buying into rising stocks is a natural impulse – and it's a viable investing strategy. Momentum investing, as it's called, is the art of finding and following the market's upward trends. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Of course, every investing style has its boosters and its bummers, and both sides usually have strong arguments in their favor. The key to success is finding balance, and remembering that while past performance won't guarantee a future return, it can still provide useful indications of where a stock is heading. With that in mind, let's dive into a pair of momentum stocks that are currently catching investors' attention. Using the TipRanks database, we've zeroed in on two names that have not only gained steam lately, but have also received bullish endorsements from at least one Street analyst. Let's take a look. BridgeBio Pharma (BBIO) The first momentum stock on our list today is BridgeBio, a biopharmaceutical company with a focus on genetic diseases that are both rare and serious. More specifically, BridgeBio has chosen disease targets with what it describes as 'clear genetic drivers'; that is, it is developing drug candidates to treat diseases that are genetically linked to single mutations. BridgeBio has chosen a rich field in which to work, as it can choose from more than 10,000 genetic diseases that meet its target criteria – and they impact tens of millions of patients globally. More importantly, this group of diseases has relatively few FDA-approved medications, giving BridgeBio plenty of openings. BridgeBio bases its development work on its proprietary drug development platform, looking for novel genetic diseases to target and then creating new medicines to address symptoms and improve patient outcomes. The company follows this development stage by moving a drug candidate from a successful clinical trial series and into the regulatory process, with commercialization being the final goal. BridgeBio reached that goal late last year. This past November, the company received FDA approval of its drug acoramidis for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM), a disease that affects the heart muscle. Treatment with acoramidis was shown in clinical trials to reduce death and hospitalization from the disease, with statistically significant improvements in patients under treatment. BridgeBio is marketing the new drug under the brand name Attruby, and 1Q25 was the company's first full quarter of commercialization efforts. The company is still investigating acoramidis in the clinical trial program, where it is the subject of the Phase 3 ACT-EARLY study, testing whether the drug is useful in preventing asymptomatic patients who carry the pathogenic TTR variant from developing the active disease. Turning to the company's financial side, we find that BridgeBio's 1Q25 earnings release showed $116.6 million in total revenues, of which $36.7 million was net product revenue derived from sales of Attruby in the US following the drug's commercial launch. The balance of the company's revenue came from license and services income. Compared to the prior-year quarter, this segment of the revenue was down by $131.2 million, leading to the total revenue year-over-year decline of 45%, although the total haul actually beat Street expectations by $58 million, aided by Atturby's better-than-expected debut. BridgeBio ran a net loss in 1Q25, of 88 cents per share, yet this was 5 cents per share better than had been expected. Investors have liked the story here and the stock shows a strong gain for the year-to-date, up ~74%. BridgeBio has caught the attention of Oppenheimer analyst Trevor Allred, who is taking a more bullish stance on the shares in light of Attruby's successful commercialization. Allred writes, 'We've been wrong on BBIO since our initiation—Bridgebio's team has executed Attruby's launch superbly, and shares have been supported by commercial outperformance and a look-ahead to clinical catalysts at YE. Our trepidation around 2029 generic entry has not mattered for 2025 stock performance. We expect share outperformance to continue as 2025 Attruby sales clear consensus estimates, and we expect commercial success to be compounded by positive clinical results from ADH1 and LGMD2i clinical trials around YE. Our concerns regarding long-term revenue durability remain, but BBIO has time to demonstrate real-world datasets demonstrating benefit over tafamidis should generics become available in 2029.' Allred follows these comments with an upgrade from Perform (i.e., Neutral) to Outperform (i.e., Buy) rating for BBIO, and a $60 price target that implies a one-year upside potential of 26%. (To watch Allred's track record, click here) Overall, this stock has earned a Strong Buy consensus rating from the Street, based on 18 recent reviews that have a lopsided breakdown of 17 Buys to 1 Hold. The shares are priced at $47.69, and their $62.75 average target price suggests that the stock will gain 31.5% by this time next year. (See BBIO stock forecast) So-Young International (SY) Next up on our list of momentum stocks is So-Young, a Chinese company. The firm that operates a social media platform, linked to the medical aesthetics industry, and connecting the varied consumers, professionals, and medical service providers in the aesthetics sector. The platform makes available reliable and trustworthy information on a carefully vetted and curated network of medical aesthetic providers. The service platform focuses on content distribution in China, making use of major social media networks and other targeted media platforms. Social media and medical aesthetics are both growth industries, and So-Young is building a brand image based on user trust, an extensive reach, and valuable data insights. So-Young's user base can trade information on clinics, the latest treatment trends in aesthetics, and the quality of treatment, all permitting better patient decisions – and based on the trust engendered by sharing personal experiences. The company is working to expand its network, to add additional medical fields such as dentistry, dermatology, ophthalmology, and basic physical exams. The service is focused on China, and the company is based in Beijing. In its financial release for 1Q25, So-Young reported important gains in the number of active users on its network and the number of verified paid visits. The active users – defined as those who had visited an aesthetic clinic at least once in the previous 12 months – totaled more than 75,500, a massive gain from the 8,000 reported in the prior-year period. The gain in verified paid visits was similar, with 45,500 in 1Q25 compared to 4,600 in 1Q24. The company reported Q1 revenue at the high end of its previously published guidance range, with a top line of RMB297.3 million (approximately US$41 million) compared with RMB318.3 million in the first quarter of 2024, a figure that beat Street expectations by $0.8 million. The shares have been on a huge runup, up 411% this year, the bulk of the gains generated over the past month and this Chinese momentum stock has come to the attention of Citi analyst Nelson Cheung, who is impressed by the company's recent growth. Cheung says of So-Young and its prospects, 'Since launch in Nov 2024, SoYoung Clinic has quickly expanded with 31 centers in major cities (Beijing, Shanghai, Shenzhen) by end-Jun, verifying SY's strength in 1) differentiating brand position for quality standardized service and value-for-money mindshare for mass public; 2) increasing pricing power over procurement as it scales up; 3) effective online private domain cross-selling for accurate targeting and site selection; 4) proven execution for profitable store management with ~80% aesthetic centers generating +ve op cash flow in 1Q. We see meaningful catalysts to drive stock price further if: 1) improving monthly sales for flagship stores in Jun (e.g. Beijing Baoli); 2) potential exploration of full managed franchising model by end 2025; 3) solid exclusive product pipeline until 2027E.' (To watch Cheung's track record, click here) Looking forward, Cheung rates this stock as a Buy, with a $5.50 price target that suggests a one-year gain for the stock of 30%. Cheung's is the only analyst review on file for this stock, which is currently trading for $4.24. (See SY stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
PCAOB chair Erica Williams to step down
The Public Company Accounting Oversight Board's (PCAOB) chair Erica Williams has decided to step down from her position. Williams was sworn in as chair in January 2022 and reappointed in October 2024. Williams said: 'With high economic uncertainty increasing the risk of fraud, the PCAOB's mission is as important as ever. It's critical that the expert PCAOB staff continue to be empowered to carry out their work of ensuring American investors are protected.' During her tenure, Williams executed a strategic plan focused on the modernisation of auditing standards, the enhancement of inspection processes, enforcement mechanisms, and the board's operational effectiveness, the PCAOB said in its press statement. Under her leadership, the PCAOB has completed access for the first time to inspect and investigate China-headquartered businesses, resulting in enforcement actions against these entities. Williams' term has been marked by various formal actions, with seven projects covering 24 rules and standards finalised during her tenure. The authority delivered sanctions, with the message that violations that put investors at risk will be met with serious consequences. Williams also oversaw the reconstitution of the Investor Advisory Group and the Standards and Emerging Issues Advisory Group. She also established the PCAOB's first-ever Office of the Investor Advocate. However, Williams' resignation comes amidst media reports suggesting that her departure was requested by Securities and Exchange Commission chairman Paul Atkins. An email sent by Williams to PCAOB staff indicated that she had been asked to resign with Atkins accepting her resignation. The email stated: 'Today, I accepted Erica Williams' offer to resign as chair and a board member of the PCAOB and thanked her for her service. I am grateful she has agreed to stay on until July 22.' Last month, the PCAOB imposed fines totalling $8.5m on the Netherlands member businesses of Deloitte, PwC, and EY for cheating in internal exams. "PCAOB chair Erica Williams to step down " was originally created and published by The Accountant, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
